Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI

Abstract

Galsulfase at two dose levels was safe and well tolerated in infants. Normal growth was maintained but skeletal abnormalities continued to progress. Urinary GAG levels decreased with treatment. Early initiation of galsulfase may prevent or slow progression of some disease manifestations.